2 results
Approved WMOCompleted
Primary: to assess the effect of intravenous (IV) ozanezumab (15 mg/kg once every 2 weeks) compared to placebo on the physical function and survival of ALS patients over a treatment period of 48-weeks.Secondary (major): other clinical outcomes,…
Approved WMOCompleted
The purpose of this study is to determine whether the application of ventricular pacing during PCI for AMI can protect the human heart from damage as a result of ischemia/reperfusion injury